New Delhi: Announcing the results for the fourth quarter ended 31st March 2020, Zydus Cadila registered total income from operations of Rs. 3752 crores, up by 3% on a Q-o-Q basis from Rs. 3638 crores registered during third quarter of the financial year 2019-20. Operating profits i.e. Earnings before Interest, Depreciation and Tax (EBIDTA) grew by 13% on a sequential basis to Rs. 791 crores during the fourth quarter. Net profit was up by 5% on a Q-o-Q basis to Rs. 392 crores. For the year ended 31st March 2020, on a consolidated basis, the Company registered the total income from operations of Rs. 14,253 crores, up by 8%.
Strengthening its regulatory pipeline, the Company filed 30 additional ANDAs during the year with the USFDA, taking the cumulative filings to 390. The Company received 28 ANDA approvals during the year, taking the total to 282 product approvals.
During the year, the Company launched the oral anti-diabetic agent, Vinglyn (Vildagliptin) and Vinglyn M (Vildagliptin plus Metformin) in India. Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India.
In a pathbreaking move in the treatment of metabolic disorders, the Company received an approval for the use of Saroglitazar in the treatment of Non-Alcoholic SteatoHepatitis (NASH). With this approval, Zydus’ Saroglitazar becomes the world’s first drug to be approved for NASH, an unmet medical need, as there is currently no approved drug for the treatment of the disease anywhere in the world. NASH is highly prevalent with 10% to 30% of the global population being affected by it. Saroglitazar is already approved for use in India to treat diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. In the last seven years, over a million patients have benefitted from this drug. In January this year, Saroglitazar also received an approval for the treatment of Type 2 Diabetes Mellitus in India.
